Tests metformin added to antidepressants for depression in obese adults
Tests metformin added to standard antidepressants in obese adults newly diagnosed with depression.
Plain-language title generated from the registry record
Registry title: Efficacy of Metformin as an Adjunct to Standard Antidepressant Therapy in Treating Depression Among Obese Patients
Key facts
- Where
- Karachi, PakistanSee the 2 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT06707012, who can take part
Where in Pakistan
- Fazaia Rurh Pfau Medical CollegeKarachi, PakistanTaking people
- Fazaia Ruth Pfau Medical CollegeKarachi, PakistanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fazaia Ruth Pfau Medical College
- Trial code
- NCT06707012
- Record updated
- 19 September 2025
- Original description
To evaluate the efficacy of metformin as an adjunct therapy in improving depressive symptoms and metabolic markers in newly diagnosed obese depressed patients on standard antidepressant therapy.Read full original descriptionShow less
Efficacy of Metformin as an Adjunct to Standard Antidepressant Therapy in Treating Depression Among Obese Patients
To evaluate the efficacy of metformin as an adjunct therapy in improving depressive symptoms and metabolic markers in newly diagnosed obese depressed patients on standard antidepressant therapy.
investigator will compare between Two groups
1. metformin group 2 placebo group Primary outcome measure will be the improvement in depressive symptoms, indicating by a reduction in Hamilton Depression Rating Scale (HAM-D) scores. Secondary outcome measures will include the assessment of oxidative stress markers, specifically by measuring the increase in enzymatic activity of superoxide dismutase, catalase, and glutathione peroxidase Investigators hypothesize that the addition of metformin to standard antidepressant treatment will result in a significant reduction in symptoms of depression among newly diagnosed obese individuals.
Inclusion: • Age >18 to <45 years; Gender: Both genders (Male and Female); BMI >25; Diagnosis: Newly diagnose cases of depression (mild to severe); HBA1C: Less than 5.7% (non-diabetic range).
Exclusion: Existing diabetes; Acute illnesses like acute kidney injury, recent history of myocardial infarction, acute liver injury; Intellectual disabilities or inability to understand due to any reason; Presence of Psychiatric disorders other than depression; Chronic kidney disease (eGFR < 45 mL/min/1.73 m²); Use of any psychotropic medication within the past 6 months.